Healthcare provider profile · identity verified

Lea Murphy

Physician Assistant · BRANFORD, CT · NPI 1043932163

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	262	78
Atorvastatin Calcium	Atorvastatin Calcium	214	55
Amlodipine Besylate	Amlodipine Besylate	213	55
Levothyroxine Sodium	Levothyroxine Sodium	211	49
Lisinopril	Lisinopril	162	44
Losartan Potassium	Losartan Potassium	135	38
Metformin Hcl	Metformin Hcl	94	24
Metoprolol Succinate	Metoprolol Succinate	87	23
Omeprazole	Omeprazole	87	17
Hydrochlorothiazide	Hydrochlorothiazide	83	25
Albuterol Sulfate Hfa	Albuterol Sulfate	77	29
Alprazolam	Alprazolam	67	17
Escitalopram Oxalate	Escitalopram Oxalate	66	19
Pantoprazole Sodium	Pantoprazole Sodium	63	19
Lorazepam	Lorazepam	62	15
Montelukast Sodium	Montelukast Sodium	57	16
Eliquis	Apixaban	53	15
Pravastatin Sodium	Pravastatin Sodium	53	17
Gabapentin	Gabapentin	50	16
Ketoconazole	Ketoconazole	49	19
Furosemide	Furosemide	48	11
Trazodone Hcl	Trazodone Hcl	46	15
Meloxicam	Meloxicam	44	16
Tamsulosin Hcl	Tamsulosin Hcl	43	16
Simvastatin	Simvastatin	41	13
Alendronate Sodium	Alendronate Sodium	40	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	39	11
Ozempic	Semaglutide	36	suppressed
Duloxetine Hcl	Duloxetine Hcl	35	11
Bupropion Xl	Bupropion Hcl	33	suppressed
Clonazepam	Clonazepam	33	suppressed
Valsartan	Valsartan	32	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	32	suppressed
Allopurinol	Allopurinol	31	12
Jardiance	Empagliflozin	31	suppressed
Metformin Hcl Er	Metformin Hcl	29	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	29	suppressed
Potassium Chloride	Potassium Chloride	28	suppressed
Sertraline Hcl	Sertraline Hcl	28	suppressed
Prednisone	Prednisone	27	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	19
Atenolol	Atenolol	26	suppressed
Ezetimibe	Ezetimibe	26	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	26	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Famotidine	Famotidine	24	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	24	12
Carvedilol	Carvedilol	22	suppressed
Diazepam	Diazepam	21	suppressed
Enalapril Maleate	Enalapril Maleate	21	suppressed
Glipizide Er	Glipizide	19	suppressed
Meclizine Hcl	Meclizine Hcl	19	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	18
Valacyclovir	Valacyclovir Hcl	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Celecoxib	Celecoxib	17	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	14
Propranolol Hcl Er	Propranolol Hcl	15	suppressed
Myrbetriq	Mirabegron	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Carvedilol Er	Carvedilol Phosphate	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	12	suppressed
Clotrimazole	Clotrimazole	12	suppressed
Diltiazem Hcl	Diltiazem Hcl	12	suppressed
Fluticasone Propionate	Fluticasone Propionate	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Nystatin	Nystatin	11	suppressed
Restasis	Cyclosporine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error